Funding Round
Neurophet raises additional $12M bridge financing ahead of US commercial launch
Korea Economic Daily4/19/2026·04/19/26🌐 Asia
Summary
Seoul-based Neurophet secured ₩16B ($12M) bridge financing from existing investors IMM Investment and Bon Angels to bridge to their planned US commercial launch of NEUROPHET AQUA brain MRI analysis software. The FDA 510(k)-cleared platform will be launched through a direct sales model targeting academic medical centers and large radiology groups.
Why it matters
Bridge financing ahead of a US commercial launch is a mature capital deployment strategy — Neurophet is funding specific commercial milestones rather than broad R&D. Their FDA clearance removes the primary US market entry barrier, and direct sales to academic centers is a proven neurotech go-to-market approach.
#AI Diagnostics#Industry#Neuroimaging#USA#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in